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Editorial on the Research Topic
New Drug Targets for Proteotoxicity in Cardiometabolic Diseases
We are honored to serve as lead editors for this Frontier theme issue of “New drug targets for
proteotoxicity in cardiometabolic diseases.” Our enthusiasm for this special topic rooted from
the recent surge of novel medications and therapeutic modalities in cardiometabolic diseases in
particular obesity, diabetes mellitus, insulin resistance, hypertension, ischemic/reperfusion injury
and myocardial infarction (Ceylan-Isik et al., 2008; Ren and Zhang, 2018; Zhang et al., 2018;
Aguilar-Ballester et al., 2021). Although development of medical technology has significantly
advanced clinical diagnosis and management for cardiometabolic diseases, the ever-rising risks of
metabolic diseases impose a main threat for health care in the 21st century (Onat, 2011; Kaur, 2014;
Ren and Anversa, 2015; Zhang et al., 2018). Up-to-date, a number of theories have been suggested
for the etiology of cardiometabolic anomalies including disturbed glucose/lipid metabolism,
endoplasmic reticulum (ER) stress, oxidative and nitrosative/nitrative stress, mitochondrial injury,
inflammation, and programmed cell death (apoptosis, necroptosis, pyroptosis, and ferroptosis)
(Ren and Kelley, 2009; Ren et al., 2010, 2021; Onat, 2011; Ceylan-Isik et al., 2013; Kaur, 2014; Ren
and Anversa, 2015). More evidence has noted an essential role for proteotoxicity or protein quality
control in the pathogenesis of cardiometabolic diseases (Sandri and Robbins, 2014; Zhang et al.,
2018). In general, protein quality control is governed by ubiquitin-proteasome system (UPS) and
autophagy-lysosomal systems, two major albeit distinct machineries for degradation and removal
of damaged and/or long-lived intracellular macromolecules (nucleic acids, proteins, carbohydrates,
lipids) and organelles (e.g., mitochondria, ribosomes, peroxisomes, and ER) (Zhang et al., 2018;
Ren et al., 2021). Interruption of UPS and autophagy evokes detrimental proteotoxic sequalae
and is drawing much attention in the pathophysiology and pharmacotherapies in cardiometabolic
diseases (Sandri and Robbins, 2014; Wang and Wang, 2014). In this context, this issue tackles
some of the burning issues in cardiometabolic diseases with a particular focus on proteotoxicity
and protein quality control.
In this issue, Li C. et al. discussed the role of Farnesoid X receptor (FXR) agonists
as a possible target for the management of cardiometabolic diseases (Li C. et al.). FXR,
a metabolic nuclear receptor, is mainly turned on by primary bile acids (BAs) such
as chenodeoxycholic acid, cholic acid and synthetic agonists such as obeticholic acid.
Recent evidence suggests that FXR agonists help to maintain regulation of cholesterol,
lipid metabolism, glucose metabolism, and intestinal microorganism, with promises in the
management of cardiometabolic diseases (Li C. et al.). Next, Tao et al. analyzed co-
expression module genes from GSE18897 and GSE47022 to reveal 6 upregulated genes.
These authors then validated upregulated levels of elongation of very-long-chain fatty
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acids protein 4, matrixmetalloproteinase-8, and interleukin-33 in
peripheral bloods from patients with obesity heart diseases. Given
the poorly defined molecular machineries underneath obesity
cardiomyopathy, findings from this integrated bioinformatics
analysis favored a role for these hub genes as potential biomarkers
for diagnosis and therapeutic targets in obesity heart diseases
(Tao et al.). In this theme issue, Yang et al. discussed the
benefits of antidiabetics metformin in the management of
diabetic cardiomyopathy. These authors found that metformin
activates prokineticin 2 (PK2), a small-molecule secreted protein
governing survival and angiogenesis, to mediate Akt/GSK3β
signaling, improve cardiac function and alleviate apoptosis in
diabetic mice (Yang et al.). In this theme issue, Tian et al.
provided insights into the complex interplay between histone
acetyltransferases (HATs) and histone deacetylases (HDACs),
two enzyme families controlling biological processes of histone
acetylation and deacetylation, in the regulation of skeletal muscle
physiology and energy homeostasis during exercise. Balance
between these two enzymes plays a major role in mitochondrial
remodeling, insulin sensitivity, on/off metabolic fuel switching
and physiological homeostasis of skeletal muscles (Tian et al.).
Type 2 diabetic patients usually display high levels of metabolic
products such as trimethylamine N-oxide (TMAO) associated
with gut dysbiosis. Here Steinke et al. discussed the value of
TMAO levels in reference to cardiovascular risk. Next, Cao
et al. examined levels of circulating ceramide in 761 patients
with comorbid acute coronary syndrome (ACS) and type 2
diabetes mellitus, and noted that circulating ceramides are
correlated with the risk of ACS-type 2 diabetes comorbidity.
These innovative results suggested the utility of ceramide levels in
the risk assessment of ACS- diabetes mellitus comorbidity (Cao
et al.). Next, Schubert et al. summarized the possible cardiac
benefits of new antidiabetic agents, including sodium-glucose
cotransporter 2 (SGLLT2) inhibitor and glucagon-like peptide-
1 receptor agonist, dipeptidyl peptidase-4 (DPP) inhibitor and
metformin in patients with high cardiovascular risk with or
without type 2 diabetes (Schubert et al.).
Myocardial ischemia injury and acute myocardial infarction
remain the leading causes of mortality in patients with
cardiovascular diseases (Zhang and Ren, 2014, 2016; Ren and
Zhang, 2017). In this theme issue, Man et al. tackled the role
of Shank3 in post-infarction cardiac dysfunction. They found
that Shank3 knockout aggravated, while Shank3 overexpression
alleviated, cardiac dysfunction following myocardial infarction.
These findings revealed a novel role for Shank3 as a new
therapeutic target for cardiac dysfunction following myocardial
infarction through induction of autophagy (Man et al.). Next,
Fu et al. succinctly dissected the compelling roles for melatonin
in acute myocardial infarction. These authors elaborated the
current well-perceived mechanisms underneath beneficial effects
of melatonin against oxidative stress, promoting autophagic
repair of cells, regulating immune and inflammatory responses,
engaging mitochondrial function, and relieving ER stress, in
the pathology of myocardial infraction injury (Fu Z. et al.).
Microtubule and mitochondrial dysfunction are involved in
cardiovascular disease etiology, including cardiac remodeling,
heart failure, and hypoxic/ischemic injury. In this issue, Li L.
et al. discussedMAP4 phosphorylation inmicrotubule instability.
Phosphorylation of MAP4 triggers mitochondrial apoptosis, en
route to cardiac injury, denoting a novel role for MAP4 as
a candidate in cardiovascular pathologies (Li L. et al.). Next,
Liu M. et al. discussed the therapeutic options for hypoxia-
related cardiovascular disease. Hypoxia-inducible factor (HIF)
is turned on in hypoxia to modulate diverse target genes.
The authors recapitulated pathophysiology of hypoxic injury
in cardiovascular disease, and provided convincing evidence
for HIF-evoked cardioprotective signaling (Liu M. et al.). Cold
stress is often associated with ischemia heart injury involving
disturbed endothelin (ET-A) receptor, ER stress, transient
receptor potential (TRP) vanilloid, mitochondrial damage. Here
Kong et al. discussed various aspects of cold stress-induced
cardiac injury, in particular dysregulated autophagy (Kong
et al.). Next, Gao et al. introduced structural and functional
characteristics of TRPA1 in cardiovascular diseases. They
discussed evidence where TRPA1 is correlated to cardiovascular
disease risk factors (Gao et al.). Exercising evokes benefits on
heart failure with preserved ejection fraction (HFpEF). Then,
Liu J. et al. designed a device to perform early passive leg
movement (ePLM) and noted benefit of ePLM in alleviating
high salt diet-induced HFpEF through inhibition of fibrosis
in a TGF-β1/Smad3-dependdent manner in conjunction to
Akt/eNOS signaling activation. These findings implied the
benefit of ePLM as a novel non-pharmacological approach
for HFpEF (Liu J. et al.). Chronic inflammation is part of
ischemic heart disease process with overt atherosclerosis. Due to
overwhelmed accumulation of monocytes/macrophages within
arterial plaques, monocytes/macrophages are deemed critical
cellular targets in the management of atherosclerosis. Many long
non-coding RNAs (LncRNAs) were found to exert regulatory
roles on metabolism and plasticity in macrophages, consequently
stimulating or inhibiting atherosclerotic inflammation. Next, Ma
et al. provided a balanced viewpoint of lncRNAs in macrophage
biology, pathogenesis and therapeutics of atherosclerosis (Ma
et al.). Furthermore, Chakafana et al. have carefully assessed
the role of heat shock proteins in peripartum cardiomyopathy,
and explored the possibility of given heat shock proteins as
novel candidate biomarkers and drug targets in peripartum
cardiomyopathy (Chakafana et al.). Next, Amin and team
discovered a cardioprotective property of an orally active
selenium based compound phenylaminoethyl selenides against
doxorubicin cardiomyopathy possibly through preserving the
stability of the iron-sulfur cluster biogenesis protein Frataxin
(FXN) (Fu X. et al.). Moreover, Zhang et al. suggest that
STAT6 plays a vital role in isoproterenol-induced β1-AR
overactivation and inflammatory response, en route to cardiac
fibrogenesis. Their findings denoted a novel role for STAT6
as a promising target against myocardial fibrosis and heart
failure (Zhang et al.). Next, Njegic et al. addressed the
molecular changes to proteins associated with Ca2+-handling
and -signaling. These authors made an in-depth analysis on
these potential novel therapeutic targets from the perspective
of both pre-clinical and, clinical settings (Njegic et al.).
In this series of collection, Ding et al. reported a novel
mechanism where angiotensin (AngII) evokes endothelial
dysfunction likely via AT1R-mediated protein phosphatase
2A (PP2A) activation to suppress endothelial nitric oxide
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synthase (eNOS) phosphorylation via Nox/ROS pathway (Ding
et al.).
Given the advances in science and technology, non-coding
(LncRNA) or microRNAs (miRNA) are considered as important
regulators of cellular processes, and serve as an important
platform for therapeutic regimen of cardiovascular disease.
Nonetheless, many questions remain unanswered for LncRNA
and miRNA, such as consequences of targeting, refinement of
targeting systems. Here Collins et al. summarized the level of
genomic regulation strategy for the treatment of cardiovascular
disease (Collins et al.). Furthermore, Yan et al. identified COX-2
and related microRNA as possible biomarkers for non-ischemic
heart failure. These authors analyzed genomic and transcription
information from peripheral blood mononuclear cells of
heart failure patients and found enrichment of prostaglandin-
endoperoxide synthase 2 (PTGS2, or cyclooxygenase-2 - COX-2),
as well as its related micro RNAs including miR-1297 and miR-
4649-3p as potential biomarkers for non-ischemic heart failure.
These authors noted overtly elevated plasma COX-2 and miR-
4649-3p I conjunction with downregulated plasma miR-1297.
Moreover, these authors suggested that miR-4649-3p possessed
high predictive power for non-ischemic heart failure (Yan et al.).
Although this theme issue did not touch too much on clinical
trials, Yang et al. did a cross-sectional survey of 241 trials
conducted on stem cell therapy. These authors shared their
“disappointment” on the outcome of these registered clinical
applications (Yang et al.).
Although this theme issue has shed some insights toward
a more thorough knowledge on possible drug targets in
cardiometabolic diseases, we regret to say we have failed in a
large part identifying specific target(s) or drug(s) on autophagy
or mitophagy molecules (the benchmarks for proteotoxic issue).
This may reflect the overall challenge and difficulty in drug
development targeting autophagy/mitophagy. Nonetheless, the
recent advances in computer-based biological modeling and
bioinformatic system should help us to better achieve desirable
chemicals to target a given protein or signaling molecule in
cardiometabolic diseases. We hope that this theme issue will aid
to unveil novel therapeutic targets to launch better intervention
regimens for cardiometabolic diseases.
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